Literature DB >> 25590535

Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.

Wojciech G Lesniak1, Emilia Sikorska, Hassan Shallal, Babak Behnam Azad, Ala Lisok, Mrudula Pullambhatla, Martin G Pomper, Sridhar Nimmagadda.   

Abstract

The CXCR4 chemokine receptor is integral to several biological functions and plays a pivotal role in the pathophysiology of many diseases. As such, CXCR4 is an enticing target for the development of imaging and therapeutic agents. Here we report the evaluation of the POL3026 peptidomimetic template for the development of imaging agents that target CXCR4. Structural and conformational analyses of POL3026 and two of its conjugates, DOTA (POL-D) and PEG12-DOTA (POL-PD), by circular dichroism, two-dimensional NMR spectroscopy and molecular dynamics calculations are reported. In silico observations were experimentally verified with in vitro affinity assays and rationalized using crystal structure-based molecular modeling studies. [(111)In]-labeled DOTA conjugates were assessed in vivo for target specificity in CXCR4 expressing subcutaneous U87 tumors (U87-stb-CXCR4) through single photon emission computed tomography (SPECT/CT) imaging and biodistribution studies. In silico and in vitro studies show that POL3026 and its conjugates demonstrate similar interactions with different micelles that mimic cellular membrane and that the ε-NH2 of lysine(7) is critical to maintain high affinity to CXCR4. Modification of this group with DOTA or PEG12-DOTA led to the decrease of IC50 value from 0.087 nM for POL3026 to 0.47 nM and 1.42 nM for POL-D and POL-PD, respectively. In spite of the decreased affinity toward CXCR4, [(111)In]POL-D and [(111)In]POL-PD demonstrated high and significant uptake in U87-stb-CXCR4 tumors compared to the control U87 tumors at 90 min and 24 h post injection. Uptake in U87-stb-CXCR4 tumors could be blocked by unlabeled POL3026, indicating specificity of the agents in vivo. These results suggest POL3026 as a promising template to develop new imaging agents that target CXCR4.

Entities:  

Keywords:  CXCR4; SPECT/CT; chemokine; chemokine receptor; molecular imaging

Mesh:

Substances:

Year:  2015        PMID: 25590535      PMCID: PMC4612581          DOI: 10.1021/mp500799q

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  44 in total

Review 1.  The design, structures and therapeutic potential of protein epitope mimetics.

Authors:  John A Robinson; Steve Demarco; Frank Gombert; Kerstin Moehle; Daniel Obrecht
Journal:  Drug Discov Today       Date:  2008-09-11       Impact factor: 7.851

2.  A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules.

Authors:  A Kumar; R R Ernst; K Wüthrich
Journal:  Biochem Biophys Res Commun       Date:  1980-07-16       Impact factor: 3.575

3.  Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity.

Authors:  H Tamamura; M Sugioka; Y Odagaki; A Omagari; Y Kan; S Oishi; H Nakashima; N Yamamoto; S C Peiper; N Hamanaka; A Otaka; N Fujii
Journal:  Bioorg Med Chem Lett       Date:  2001-02-12       Impact factor: 2.823

4.  Comparison of the conformation and electrostatic surface properties of magainin peptides bound to sodium dodecyl sulfate and dodecylphosphocholine micelles.

Authors:  Rickey P Hicks; Erin Mones; Hanah Kim; Brandon W Koser; Daniel A Nichols; Apurba K Bhattacharjee
Journal:  Biopolymers       Date:  2003-04       Impact factor: 2.505

Review 5.  The significance of cancer cell expression of the chemokine receptor CXCR4.

Authors:  Fran Balkwill
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

6.  64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Authors:  Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter
Journal:  Bioorg Med Chem       Date:  2009-01-15       Impact factor: 3.641

Review 7.  Imaging agents for the chemokine receptor 4 (CXCR4).

Authors:  Joeri Kuil; Tessa Buckle; Fijs W B van Leeuwen
Journal:  Chem Soc Rev       Date:  2012-06-28       Impact factor: 54.564

8.  1H, 13C and 15N chemical shift referencing in biomolecular NMR.

Authors:  D S Wishart; C G Bigam; J Yao; F Abildgaard; H J Dyson; E Oldfield; J L Markley; B D Sykes
Journal:  J Biomol NMR       Date:  1995-09       Impact factor: 2.835

9.  Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.

Authors:  Sridhar Nimmagadda; Mrudula Pullambhatla; Martin G Pomper
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

Review 10.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

View more
  5 in total

1.  In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.

Authors:  Wojciech G Lesniak; Teshome Aboye; Samit Chatterjee; Julio A Camarero; Sridhar Nimmagadda
Journal:  Chemistry       Date:  2017-08-03       Impact factor: 5.236

2.  Rational design of cell-permeable cyclic peptides containing a d-Pro-l-Pro motif.

Authors:  Jin Wen; Hui Liao; Kye Stachowski; Jordan P Hempfling; Ziqing Qian; Chunhua Yuan; Mark P Foster; Dehua Pei
Journal:  Bioorg Med Chem       Date:  2020-08-18       Impact factor: 3.641

3.  Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas.

Authors:  Dustin Wayne Demoin; Masahiro Shindo; Hanwen Zhang; Kimberly J Edwards; Inna Serganova; Naga Vara Kishore Pillarsetty; Jason S Lewis; Ronald G Blasberg
Journal:  Nucl Med Biol       Date:  2016-05-14       Impact factor: 2.408

4.  A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.

Authors:  Samit Chatterjee; Wojciech G Lesniak; Matthew Gabrielson; Ala Lisok; Bryan Wharram; Polina Sysa-Shah; Babak Behnam Azad; Martin G Pomper; Sridhar Nimmagadda
Journal:  Oncotarget       Date:  2016-03-01

5.  An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications.

Authors:  Wojciech G Lesniak; Babak Behnam Azad; Samit Chatterjee; Ala Lisok; Martin G Pomper
Journal:  Pharmaceutics       Date:  2022-03-16       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.